Argenx Se (ARGX) EBITDA Margin Growth (5y) (2021 - 2026)
Powered by 
Analysis
Argenx Se (ARGX) EBITDA Margin Growth (5y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | Incyte | 25.59 Bn | 21.05 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -6,996.00 |
| Mar 31, 2026 | 3,036.00 |
| Dec 31, 2025 | -1.13 Mn |
| Sep 30, 2025 | 135,474.00 |
| Jun 30, 2025 | 928,274.00 |
| Mar 31, 2025 | -48,660.00 |
| Dec 31, 2024 | 44,322.00 |
| Sep 30, 2024 | 56,236.00 |
| Jun 30, 2024 | 67,456.00 |
| Mar 31, 2024 | -688.00 |
| Dec 31, 2023 | 218,190.00 |
| Sep 30, 2023 | 106,245.00 |
| Jun 30, 2023 | 5,318.00 |
| Mar 31, 2023 | 20,638.00 |
| Dec 31, 2022 | 38,958.00 |
| Sep 30, 2022 | -49,758.00 |
| Jun 30, 2022 | 10,342.00 |
| Mar 31, 2022 | -92,635.00 |
| Dec 31, 2021 | -97,821.00 |
| Sep 30, 2021 | 93,646.00 |